Phenergan

(Promethazine)

ApprovedSmall molecule

BBassett Healthcare

Phenergan is one of 94 small molecule programs targeting Gastroparesis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

GastroparesisActive, not recruiting

VertigoActive, not recruiting

Nausea and VomitingActive, not recruiting

Motion SicknessActive, not recruiting

GastroparesisPhase 2

Active, not recruiting

VertigoPhase 3

Active, not recruiting

Nausea and VomitingPreclinical

Active, not recruiting

Motion SicknessApproved

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Nausea and Vomiting

#DrugCompanyPhaseTrials

Phenergan

BBassett Healthcare

Approved

5 2

Aloxi

AAvyxa

Preclinical

27 3

Alfenta

Alnylam Pharmaceuticals

Preclinical

1 4

Ramosetron

Astellas

Preclinical

15 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

7 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Haldol

DDePuy Orthopaedics

Preclinical

3 8

Adriamycin

GGynecologic Oncology Group

Preclinical

2 9

Cytoxan

BBaxter Healthcare Corporation

Preclinical

2 10

Versed

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nausea and vomiting5 trials

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Completed·VVanderbilt University·N/A·NCT02625181·27,034 enrolled

Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting

Completed·SSergio Bergese·Phase 4·NCT01474915·122 enrolled

Efficacy of Low Dose Promethazine for Postoperative Nausea and Vomiting

Terminated·WWomen's College Hospital·N/A·NCT01159548·400 enrolled

Show 2 more trials

A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department

Completed·UUniversity of New Mexico·Phase 4·NCT00429832·120 enrolled

Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED

Terminated·VVanderbilt University·N/A·NCT00655642·171 enrolled

Single Dose1 trial

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Completed·IIndivior Inc.·Phase 4·NCT01846455·43 enrolled

Labor Pain1 trial

Effect of Hyoscine and Promethazine on Labor Pain

Completed·MMashhad University of Medical Sciences·Phase 2/3·NCT01644838·93 enrolled

Motion Sickness1 trial

Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels

Completed·FFaisal_Karmali@MEEI.HARVARD.EDU·Phase 4·NCT02136420·30 enrolled

Vertigo1 trial

Promethazine vs. Lorazepam for Treatment of Vertigo

Completed·SShahid Beheshti University of Medical Sciences·Phase 3·NCT01827293·210 enrolled

6 more indications

Gastroparesis1 trial

Study of Promethazine for Treatment of Diabetic Gastroparesis

Terminated·—·Phase 2·NCT02130622·3 enrolled

Pruritus1 trial

Treatment of Pruritus With Intramuscular Promethazine

Completed·UUniversity of Florida·Phase 4·NCT04805073·72 enrolled

Nitrous Oxide1 trial

Effects of Oral Midazolam in Comparison Promethazine With Nitrous Oxide for Uncooperative Children

Unknown status·SShahid Beheshti University·Phase 3·NCT01118884·20 enrolled

Endoscopic Retrograde Cholangiopancreatography (ERCP)1 trial

Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures

Completed·UUniversity of California, Irvine·Phase 4·NCT00937924·304 enrolled

Crohn's Disease1 trial

Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

Completed·UUniversity of Pennsylvania·Phase 2·NCT02765256·8 enrolled

Unspecified1 trial

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

PHENERGAN

NDA NDA008857

Jan 1, 1982

PHENERGAN

NDA NDA010926

Jan 1, 1982

PHENERGAN

NDA NDA011689

Jan 1, 1982

PHENERGAN

NDA NDA007935

Apr 18, 1984

PROMETHAZINE HYDROCHLORIDE PLAIN

NDA NDA008381

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Promethazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Promethazine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Promethazine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA008381). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bassett Healthcare company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: BBassett Healthcare

Phenergan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nausea and vomiting5 trials

Single Dose1 trial

Labor Pain1 trial

Motion Sickness1 trial

Vertigo1 trial

Gastroparesis1 trial

Pruritus1 trial

Nitrous Oxide1 trial

Endoscopic Retrograde Cholangiopancreatography (ERCP)1 trial

Crohn's Disease1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News